Tag: NCT03145181

Home / NCT03145181

Categories

Teclistamab-cqyv is approved by FDA for relapsed or refractory multiple myeloma

November 2022: The first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), was given accelerated approval by the Food and Dru...
nct03145181

Scan the code